Marcus Jewell Sells 12,658 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Marcus Jewell also recently made the following trade(s):

• On Tuesday, May 12th, Marcus Jewell sold 383 shares of Cellebrite DI stock. The stock was sold at an average price of $13.01, for a total transaction of $4,982.83.

Cellebrite DI Trading Down 0.4%

CLBT stock opened at $13.40 on Thursday. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98. The company’s 50 day moving average is $13.44 and its two-hundred day moving average is $15.42. The stock has a market cap of $3.34 billion, a P/E ratio of 47.86, a PEG ratio of 1.61 and a beta of 1.15.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Needham & Company LLC cut their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Finally, Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.75.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently modified their holdings of the business. CWM LLC increased its holdings in shares of Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after acquiring an additional 720 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its holdings in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at $40,000. First Horizon Corp increased its holdings in shares of Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the period. Finally, Vestcor Inc acquired a new position in Cellebrite DI in the 3rd quarter valued at about $70,000. 45.88% of the stock is owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.